IGF::OT::IGF: SBIR PHASE II, TOPIC 326: DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS THAT TARGET CANCER STEM CELLS

Information

• Research Project
• 9361090

• ApplicationId

  9361090

• Core Project Number

  N44CA000000

• Full Project Number

  261201600043C-0-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  9/19/2016 - 9 years ago

• Project End Date

  9/18/2018 - 7 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2016

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• CELLERANT THERAPEUTICS INC

The effectiveness of current AML treatments is abysmal yielding only an overall 5-year survival rate of ~25%, and it has been hypothesized that the treatment may be more durable if leukemic stem cells (LSC) are eliminated. IL1RAP is a compelling target because it is expressed on LSC in majority of AML patients, but not on healthy hematopoietic stem cells. Also, suppressing IL1RAP expression in AML cells can greatly inhibit tumor cell growth/survival. From SBIR Phase I contract, the contractor developed various antibodies against IL1RAP having functional blocking properties, a higher affinity for membrane-bound IL1RAP relative to the secreted form, and tumor cell inhibition activities.

IC Name

• Activity

  N44

• Administering IC

  CA

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  1496276

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:1496276\

• Funding Mechanism

  SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  CELLERANT THERAPEUTICS, INC.

• Organization Department

• Organization DUNS

  123959400

• Organization City

  SAN CARLOS

• Organization State

  CA

• Organization Country

  UNITED STATES

• Organization Zip Code

  940704111

• Organization District

  UNITED STATES